Kingsview Wealth Management LLC Purchases 1,559 Shares of Johnson & Johnson (NYSE:JNJ)

Kingsview Wealth Management LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the 1st quarter, Holdings Channel reports. The fund owned 137,942 shares of the company’s stock after purchasing an additional 1,559 shares during the period. Kingsview Wealth Management LLC’s holdings in Johnson & Johnson were worth $21,821,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Alpha Family Trust raised its position in shares of Johnson & Johnson by 180.0% during the 1st quarter. Alpha Family Trust now owns 6,230 shares of the company’s stock valued at $986,000 after buying an additional 4,005 shares in the last quarter. TBH Global Asset Management LLC raised its position in Johnson & Johnson by 2.2% during the first quarter. TBH Global Asset Management LLC now owns 21,955 shares of the company’s stock valued at $3,473,000 after purchasing an additional 482 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Johnson & Johnson by 18.7% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,072,073 shares of the company’s stock valued at $485,964,000 after purchasing an additional 483,115 shares during the last quarter. Foundry Partners LLC boosted its holdings in shares of Johnson & Johnson by 29.1% in the 1st quarter. Foundry Partners LLC now owns 154,865 shares of the company’s stock worth $24,498,000 after purchasing an additional 34,949 shares during the period. Finally, Interchange Capital Partners LLC increased its position in shares of Johnson & Johnson by 15.4% during the 1st quarter. Interchange Capital Partners LLC now owns 2,559 shares of the company’s stock valued at $413,000 after purchasing an additional 342 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $0.57 during mid-day trading on Friday, hitting $154.85. The stock had a trading volume of 3,778,462 shares, compared to its average volume of 7,309,380. The firm has a market cap of $372.67 billion, a PE ratio of 9.64, a PEG ratio of 2.76 and a beta of 0.52. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The company has a 50 day moving average of $148.26 and a two-hundred day moving average of $153.40. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.79% and a net margin of 46.34%. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the prior year, the firm earned $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.20%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on JNJ. Bank of America reduced their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. TD Securities decreased their target price on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, July 1st. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 30th. Finally, HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $175.00.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.